• Abiraterone Acetate: CYP17 Research Guide

  2026-09-14

  Abiraterone acetate is a CYP17 inhibitor used to study androgen biosynthesis pathway dependence in prostate cancer research. This guide separates product-specific assay benchmarks from evidence generated with patient-derived three-dimensional spheroids.

• Bufalin Targets STK33 in Triple-Negative Breast Cancer

  2026-09-14

  A 2025 Advanced Science study identifies STK33 as a binding target and degradation-sensitive dependency of Bufalin in triple-negative breast cancer. By combining affinity-based target discovery, genetic perturbation, mechanistic analysis, animal models, and patient-derived organoids, the work connects STK33 destabilization with suppression of tumor growth.

• ac4C Improves Synthetic mRNA Translation and Fidelity

  2026-09-13

  The reference study identifies N4-acetylcytidine (ac4C) as an alternative to m1Ψ that can increase synthetic mRNA protein output without increasing inflammatory responses. Its central mechanistic finding is that translation elongation rate, ribosome collisions, and quality-control pathways can determine mRNA yield even when ribosome loading is similar.

• AAPH Oxidative Stress Assay Workflows

  2026-09-12

  AAPH delivers a sustained, water-compatible peroxyl-radical challenge for erythrocyte hemolysis, lipid peroxidation, and antioxidant screening. This practical guide links assay design to the PRDX6–GPX4 ferroptosis pathway while separating useful model features from claims that require cellular or tumor validation.

• ARCA Cy3 EGFP mRNA (5-moUTP) Guide

  2026-09-11

  ARCA Cy3 EGFP mRNA (5-moUTP) is a direct-detection reporter for studying delivery, intracellular localization, and EGFP expression. This 5-methoxyuridine modified mRNA combines Cy3 fluorescence, ARCA capping, and a reported 5-moU formulation to support controlled mRNA transfection in mammalian cells.

• Rhodamine B: From Drift Tracer to Assay Signal

  2026-09-11

  Rhodamine B connects environmental spray-drift mapping with carefully controlled fluorescence workflows. This article explains how Basic Violet 10 converts transport and deposition into defensible assay data while identifying the limits of cross-domain interpretation.

• I-BET151: A Causal Map of BET Cancer Biology

  2026-09-10

  I-BET151 (GSK1210151A) can do more than suppress BET-dependent transcription: it can help researchers test causal links between enhancer control, tumor-state adaptation, apoptosis, and disulfidptosis. This article integrates the compound’s pharmacology with a recent prostate cancer study to develop a more discriminating assay strategy.

• Cycloheximide in Translation-Linked Cancer Assays

  2026-09-10

  Cycloheximide is more than a translation inhibitor: it is a causal tool for separating protein synthesis from protein stability in cancer and apoptosis research. This guide connects translational elongation blockade with RPN1–PD-L1 biology and practical assay design.

• Torin2 and Pol II: Smarter Apoptosis Assays

  2026-09-09

  Explore how Torin2, a potent mTOR inhibitor, can be used to distinguish pathway suppression from active apoptosis. This guide integrates mTOR pharmacology with the 2025 Cell study of Pol II degradation-dependent cell death to improve assay design and interpretation.

• AEBSF.HCl in Protease and Necroptosis Assays

  2026-09-09

  AEBSF.HCl provides irreversible, broad-spectrum serine protease inhibition for cell lysates, amyloid precursor protein studies, and leukemic-cell lysis assays. Its most valuable role in necroptosis experiments is as an orthogonal serine-protease probe—not a substitute for cathepsin B inhibition—helping researchers separate protease classes during lysosomal membrane permeabilization studies.

• Anti-b, mTOR Signaling, and Hepatic Steatosis

  2026-09-08

  The reference study shows that Anti-b reduces diet- and oleic acid-induced dyslipidaemia and hepatic lipid accumulation in animal and cellular models. Its central mechanistic contribution is the linking of Anti-b-associated mTOR engagement with reduced mTOR phosphorylation and downstream suppression of PPARγ and SREBP1 signalling.

• CCT007093: A Practical PPM1D Inhibitor Workflow

  2026-09-08

  CCT007093 enables mechanism-focused studies of PPM1D/WIP1, P38 kinase activation, and stress-linked cytotoxicity. This workflow connects biochemical inhibition with breast cancer and renal injury assays while emphasizing DMSO handling, temporal controls, and orthogonal validation.

• Birinapant (TL32711) in Apoptosis Research

  2026-09-07

  Birinapant (TL32711) is a bivalent SMAC mimetic IAP antagonist that targets cIAP1, cIAP2, XIAP, and ML-IAP. Its reported mechanism links IAP antagonism to TNF-mediated NF-κB inhibition, caspase-8 activation, TRAIL potency enhancement, and apoptosis induction in cancer cells, while MDM1 evidence provides a separate biomarker framework for colorectal cancer chemoradiotherapy.

• FH1 Small Molecule for Hepatocyte Maturation

  2026-09-07

  FH1 is a small molecule for cultured hepatocyte function enhancement during iPS cell differentiation to hepatocytes. Product information reports approximately 2-fold higher albumin secretion, larger hepatocyte-like cell colonies, increased CYP3A4, and reduced AFP under the described differentiation context.

• Cefotaxime Workflows for Resistance Research

  2026-09-05

  Cefotaxime connects beta-lactam activity, resistance phenotyping, and controlled bacterial infection models without treating one susceptibility result as a complete mechanism. This practical guide shows how to build reproducible assays, interpret plasmid-associated resistance, and troubleshoot stability or genotype–phenotype discordance.

8710 records 2/581 page Previous Next 12345 下5页 Last page